Guidelines for the management of Parkinson's disease. The Parkinson's Disease Consensus Working Group.
Parkinson's disease is a chronic and disabling illness and there is currently wide variation in its management. This article presents the first UK-specific guidelines for the management of Parkinson's disease and it contains a treatment decision free to aid the physician in deciding when and how to treat patients. We hope this document will prove useful to all those involved in the planning and delivery of care to patients with Parkinson's disease.
University Department of Clinical Neurology, Institute of Neurology, London.
K
K
Bhatia
D J
DJ
Brooks
D J
DJ
Burn
C E
CE
Clarke
J
J
Playfer
G V
GV
Sawle
A H
AH
Schapira
D
D
Stewart
A C
AC
Williams
D000368:Aged; D000465:Algorithms; D000547:Amantadine / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000627:therapeutic use; D065098:Catechol O-Methyltransferase Inhibitors; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D003937:Diagnosis, Differential; D018491:Dopamine Agonists / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D010300:Parkinson Disease / Q000175:diagnosis / Q000628:therapy*; D010347:Patient Care Planning
D000978:Antiparkinson Agents; D065098:Catechol O-Methyltransferase Inhibitors; D018680:Cholinergic Antagonists; D018491:Dopamine Agonists; D008996:Monoamine Oxidase Inhibitors; D007980:Levodopa; D000547:Amantadine